News

Morningstar22d
IDeate-Prostate01 Phase 3 Trial of Ifinatamab Deruxtecan Initiated in Patients with Pretreated Metastatic Castration-Resistant Prostate Cancer - Morningstar
The first patient has been dosed in the IDeate-Prostate01 phase 3 trial evaluating the efficacy and safety of investigational ifinatamab deruxtecan (I-DXd) versus docetaxel in patients with ...
Morningstar1mon
IDeate-Esophageal01 Phase 3 Trial of Ifinatamab Deruxtecan Initiated in Certain Patients with Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma - Morningstar
IDeate-Esophageal01 will enroll approximately 510 ... (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities ...
Nasdaq1mon
IDeate-Esophageal01 Phase 3 Trial of Ifinatamab Deruxtecan ... - Nasdaq
IDeate-Esophageal01 will enroll approximately 510 ... (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities ...
Seeking Alpha11mon
IDeate-Lung02 Phase 3 Trial of Ifinatamab Deruxtecan Initiated in Patients with Relapsed Small Cell Lung Cancer - Seeking Alpha
IDeate-Lung02 Phase 3 Trial of Ifinatamab Deruxtecan Initiated in Patients with Relapsed Small Cell Lung Cancer Aug. 01, 2024 8:00 AM ET Merck & Co., Inc. (MRK) , DSNKY Q2: 2024-07-30 Earnings Summary ...